Antimicrobial and anticancer effects of some 2-(substitutedsulfanyl)-N-(5- methyl-isoxazol-3-yl)acetamide derivatives

Medicinal Chemistry Research

Volumn 22, Issue 1, 2013, Pages 211-218

  Özkay, Yusuf ^a   Incesu, Zerrin ^a   Önder, Nur Ipek ^a   TunalI, Yaǧmur ^a   Karaca, Hülya ^a   IśIkdaǧ, Ilhan ^a   Uçucu, Ümit ^a  

^a ANADOLU UNIVERSITY   (Turkey)

Author keywords

Antibacterial; Anticancer; Antifungal; Azole; Isoxazole

Indexed keywords

2 (1 METHYL 1H 1,2,4 TETRAZOL 5 YL)SULFANYL N (5 METHYLISOXAZOL 3 YL)ACETAMIDE; 2 (1 METHYL 1H IMIDAZOL 2 YL)SULFANYL N (5 METHYLISOXAZOL 3 YL)ACETAMIDE; 2 (1 PHENYL 1H 1,2,3,4 TETRAZOL 5 YL)SULFANYL N (5 METHYLISOXAZOL 3 YL)ACETAMIDE; 2 (1H BENZIMIDAZOL 2 YL)SULFANYL N (5 METHYLISOXAZOL 3 YL)ACETAMIDE; 2 (4 METHYL 4H 1,2,4 TRIAZOL 3 YL)SULFANYL N (5 METHYLISOXAZOL 3 YL)ACETAMIDE; 2 (4H 1,2,4 TRIAZOL 3 YL)SULFANYL N (5 METHYLISOXAZOL 3 YL)ACETAMIDE; 2 (5 METHYL 1,3,4 THIADIAZOL 2 YL)SULFANYL N (5 METHYLISOXAZOL 3 YL)ACETAMIDE; 2 (BENZOTHIAZOL 2 YL)SULFANYL N (5 METHYLISOXAZOL 3 YL)ACETAMIDE; 2 (BENZOXAZOL 2 YL)SULFANYL N (5 METHYLISOXAZOL 3 YL)ACETAMIDE; 2 PHENYLSULFANYL N (5 METHYLISOXAZOL 3 YL)ACETAMIDE; ACETAMIDE DERIVATIVE; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; KETOCONAZOLE; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASSAY; CELL STRAIN HT29; DNA SYNTHESIS; DRUG STRUCTURE; DRUG SYNTHESIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; HUMAN CELL; MELANOMA CELL; SUBSTITUTION REACTION;

EID: 84872030790     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-012-0021-2     Document Type: Article

References (46)

1. Al-Masoudi A, Al-Soud YA, Al-Salihi NJ, Al-Masoudi NA (2006) 1,2,4-Triazoles: synthetic approaches and pharmacological importance. Chem Heterocycl Compd 42:1377-1403
2. Baginski M, Fogolari F, Briggs JM (1997) Electrostatic and non-electrostatic contributions to the binding free energies of anthracycline antibiotics to DNA. J Mol Biol 274:253-267
3. Brantley E, Trapani V, Alley MC, Hose CD, Bradshaw TD, Stevens MFG, Sausville EA, Stinson SF (2004) Fluorinated 2-(4-amino-3-methylphenyl) benzothiazoles induce CYP1A1 expression, become metabolized and bind to macromolecules in sensitive human cancer cells. Drug Metab Dispos 32:1392-1401
4. Cragg GM, Newman DJ (2005) Plants as a source of anti-cancer agents. J Ethnopharmacol 100:72-79
5. Cragg GM, Grothaus PG, Newman DJ (2009) Impact of natural products on developing new anti-cancer agents. Chem Rev 109:3012-3043
6. Fazeny-Dorner B, Veitl M, Wenzel C, Piribauer M, Rossler K, Dieckmann K, Ungersbock K, Marosi C (2003) Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme. Anticancer Drugs 14:437-442
7. Finlay GJ, Baguley BC (1990) Potentiation by phenylbisbenzimidazoles of cytotoxicity of anticancer drugs directed against topoisomerase II. Eur J Cancer 26:586-589
8. Geierstanger B, Wemmer DE (1995) Complexes of the minor groove of DNA. Annu Rev Biophys Biomol Struct 24:463-493
9. Harshman KD, Dervan PB (1985) Molecular recognition of β-DNA by Hoechst 33258. Nucleic Acids Res 13:4825-4835
10. Hose CD, Hollingshead M, Sausville EA, Monks A (2003) Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5-fluoro- benzothiazole: a potential surrogate marker for patient sensitivity. Mol Cancer Ther 2:1265-1272
11. Jackman AL, Kimbell R, Aherne GW, Brunton L, Jansen G, Stephens TC, Smith MN, Wardleworth JM, Boyle FT (1997) Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase. Clin Cancer Res 3:911-921
12. Kamal A, Reddy JS, Ramaiah MJ, Dastagiri D, Bharathi EV, Azhar MA, Sultana F, Pushpavalli SN, Pal-Bhadra M, Juvekar A, Sen S, Zingde S (2010) Design, synthesis and biological evaluation of 3,5-diaryl-isoxazoline/isoxazole- pyrrolobenzodiazepine conjugates as potential anticancer agents. Eur J Med Chem 45:3924-3937
13. Kaplancikli ZA, Turan-Zitouni G, Revial G, Guven K (2004) Synthesis and study of antibacterial and antifungal activities of novel 2-[[(benzoxazole/ benzimidazole-2-yl)sulfanyl]acetylamino]thiazoles. Arch Pharm Res 24:1081-1085
14. Karikas GA, Schulpis KH, Reclos G, Kokotos G (1998) Measurement of molecular interaction of aspartame and its metabolites with DNA. Clin Biochem 31:405-407
15. Kumar D, Jacob MR, Reynolds MB, Kerwin SM (2002) Synthesis and evaluation of anticancer benzoxazoles and benzimidazoles related to UK-1. Bioorg Med Chem 10:3997-4004
16. Lee YS, Park SM, Kim HM, Park SK, Lee K, Lee CW, Kim BH (2009) C5-Modified nucleosides exhibiting anticancer activity. Bioorg Med Chem Lett 19:4688-4691
17. Lloyd DG, Golfis G, Knox AJ, Fayne D, Meegan MJ, Oprea TI (2006) Oncology exploration: charting cancer medicinal chemistry space. Drug Discov Today 11:149-159
18. Malíková J, Swaczynová J, Kolár Z, Strnad M (2008) Anticancer and antiproliferative activity of natural brassinosteroids. PhytochemIstry 69:418-426
19. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M (2006) Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46:249-279
20. Moore MH, Hunter WN, d'Estaintot BL, Kennard O (1989) DNA-drug interactions. The crystal structure of d(CGATCG) complexed with daunomycin. J Mol Biol 206:693-705
21. Neidle S (2008) Principles of nucleic acid structure, 5. Principles of small molecule DNA recognition. Elsevier, Amsterdam, pp 132-203
22. Nelson JA, Rose LM, Benneft LL (1977) Mechanism of action of 2-amino-1,3,4-thiadiazole (NSC 4728). Cancer Res 37:182-187
23. Ozdemir A, Turan-Zitouni G, Kaplancikli ZA, Revial G, Demirci F, IŚcan G (2010) Preparation of some pyrazoline derivatives and evaluation of their antifungal activities. J Enzyme Inhib Med Chem 25:565-571
24. Ozkay Y, TunalI Y, Karaca H, IŚIkdaǧ I (2011) Antimicrobial activity of a new combination system of benzimidazole and various azoles. Arch Pharm 344:264-271
25. Patil M, Hunoor R, Gudasi K (2010) Transition metal complexes of a new hexadentate macroacyclic N2O4-donor Schiff base: inhibitory activity against bacteria and fungi. Eur J Med Chem 45:2981-2986
26. Pechan PM (1991) Heat shock proteins and cell proliferation. FEBS Lett 280:1-4
27. Perez-Ruixo JJ, Piotrovskij V, Zhang S, Hayes S, DePorre P, Zannikos P (2006) Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients. Br J Clin Pharmacol 62:81-96
28. Pindur U, Haber M, Sattler K (1993) Antitumor active drugs as intercalators of deoxyribonucleic acid: molecular models of intercalation complexes. J Chem Educ 70:263-272
29. Popiolkiewicz J, Polkowski K, Skierski JS, Mazurek AP (2005) In vitro toxicity evaluation in the development of new anticancer drugs-genistein glycosides. Cancer Lett 229:67-75
30. Reddy CVN, Raju S, Reddy MN, Rajanarendar E (2010) Synthesis of N-1-(3,5-dimethyl-4-isoxozolyl)-3- (4-aryl-5-thioxo-4,5-dihydro-1-H-1,2,4- triazol-3-yl)propanamides (III) as possible antitumor agents. Indian J Chem 49B:1667-1670
31. Rehn C, Pindur U (1996) Model building and molecular mechanics calculations of mitoxantrone-deoxytetranucleotide complexes: molecular foundations of DNA intercalation as cytostatic active principle. Monatsh Chem 127:631-644
32. Rida SM, Ashour FA, El-Hawash SAM, Elsemary MM, Badr MH, Shalaby MA (2005) Synthesis of some novel benzoxazole derivatives as anticancer, anti-HIV-1 and antimicrobial agents. Eur J Med Chem 40:949-959
33. Rozhkova EA, Lysko AI, Kuleshov KV, Evstigneeva RP (2000) The synthesis and antioxidant activity of azole derivatives of hemin. Russ J Bioorg Chem 26:419-422
34. Sarkar B, Dosch J, Simeone DM (2009) Cancer stem cells: a new theory regarding a timeless disease. Chem Rev 109:3200-3208
35. Satz AL, White CM, Beerman TA, Bruice TC (2001) Double-stranded DNA binding characteristics and subcellular distribution of a minor groove binding diphenyl ether bisbenzimidazole. Biochemistry 40:6465-6474
36. Shui X, Peek ME, Lipscomb LA, Wilkinson AP, Williams LD, Gao M, Ogata C, Roques BP, Garbay-Jaureguiberry C (2000) Effects of cationic charge on three-dimensional structures of intercalative complexes: structure of a bis-intercalated DNA complex solved by MAD phasing. Curr Med Chem 7:59-71
37. Sreedhar AS, Csermely P (2004) Heat shock proteins in the regulation of apoptosis: new strategies in tumor therapy: a comprehensive review. Pharmacol Ther 101:227-257
38. Sztanke K, Tuzimski T, Rzymowska J, Pasternak K, Kandefer-Szerszen M (2008) Synthesis, determination of the lipophilicity, anticancer and antimicrobial properties of some fused 1,2,4-triazole derivatives. Eur J Med Chem 43:404-419
39. Testa B, Crivori P, Reist M, Carrupt PA (2000) The influence of lipophilicity on the pharmacokinetic behavior of drugs: concepts and examples. Perspect Drug Discov Des 19:179-211
40. Thurston DE (2007) Chemistry and pharmacology of anticancer drugs. CRC Press, Boca Raton
41. Varache-Lembège M, Moreau S, Larrouture S, Montaudon D, Robert J, Nuhrich A (2008) Synthesis and antiproliferative activity of aryl- and heteroaryl-hydrazones derived from xanthone carbaldehydes. Eur J Med Chem 43:1336-1343
42. Vekariya NA, Khunt MD, Parikh AR (2003) Synthesis of isoxazoles and quinoxalines as potential anticancer agents. Indian J Chem 42B:421-424
43. Villanueva T (2010) Cancer stem cells: Wnt-looking outside in. Nat Rev Cancer 10:386-387
44. Waring MJ, Bailly C (1994) The purine 2-amino group as a critical recognition element for binding of small molecules to DNA. Gene 149:69-79
45. Wayne PA (2006) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically approved standard, 7th edn. CLSI Document M7-A7
46. Zhigang L, Qing Y, Xuhong Q (2005) Synthesis, antitumor evaluation and DNA photocleaving activity of novel methylthiazonaphthalimides with aminoalkyl side chains. Bioorg Med Chem Lett 15:3143-3146